September 27, 2025 • 4 mins
Welcome back, listeners, to Ozempic Weightloss Unlocked. Today, we are uncovering the latest news and updates on Ozempic, from its medical applications to its influence on our daily lives and overall health.
There is an exciting development in the world of weight loss medication: a pill form of Ozempic, known by its generic name semaglutide. According to The New England Journal of Medicine, those who took the daily semaglutide pill lost nearly fourteen percent of their body weight over sixty-four weeks, compared to just two percent for those who took a placebo. This makes oral semaglutide a potential game changer for those who prefer pills over injections, especially since the pill shows a safety profile similar to the injectable form. Dr. Sean Wharton, who led the recent clinical trial, explained that this oral option could greatly expand the number of people willing to try GLP-1 treatments for obesity.
Following closely behind is orforglipron, a new GLP-1 pill developed by Eli Lilly. Fox News reports that in a recent clinical trial, participants taking the highest dose of orforglipron lost an average of more than twenty-seven pounds after a year and a half. Nearly sixty percent of those participants lost ten percent of their body weight, while just under forty percent lost at least fifteen percent. What is even more hopeful, according to the study published in The New England Journal of Medicine, is that those with pre-diabetes saw a sharp improvement in blood sugar levels, suggesting broad metabolic benefits. While the results are compelling, experts note that injectables like Ozempic still deliver slightly more dramatic results, yet many patients may prefer the convenience and ease of a pill.
On a different front, research from The Cleveland Clinic has revealed that genetics may influence just how well Ozempic or similar drugs work for you. According to their study, a gene known as Neurobeachin appears to help determine how much weight a person might lose with GLP-1 medications. People with a responsive version of the gene were eighty-two percent more likely to have significant weight loss, while those with a non-responsive score were actually less likely to lose weight. Dr. Daniel Rotroff from the Cleveland Clinic suggests that in the near future, doctors could combine genetic testing with lifestyle and personal factors to tailor obesity treatment, making these therapies even more effective and personalized.
Let us not forget the reason why Ozempic was developed in the first place. Originally designed and approved to help manage type two diabetes, Ozempic as well as its higher-dose sibling Wegovy, are now also used for chronic weight management. Both are part of a class called glucagon-like peptide-1 receptor agonists, or GLP-1s. These medications work by stimulating insulin production and helping the body manage appetite and digestion, leading to weight loss as a beneficial side effect. According to information from the Lawsuit Information Center, Ozempic is still mainly prescribed as a once-weekly injection, but with oral versions nearing approval, that could soon change.
New treatments often come with questions about safety. According to the United States Food and Drug Administration, there has been increased concern about unapproved compounded versions of these GLP-1 drugs, which have been linked to hundreds of adverse event reports. This highlights the importance of using only medications that are properly prescribed and approved, as safety must always come first.
Finally, there are ongoing investigations into rare but serious side effects, such as a risk of vision loss, and digestive issues like gastroparesis linked to GLP-1 drugs including Ozempic. For most people, side effects tend to be mild and include nausea and digestive discomfort, but it is crucial to talk to your doctor to understand the potential risks and benefits as this new generation of weight loss options emerges.
That wraps up our update on Ozempic and the evolving world of GLP-1 weight loss therapies. Thanks for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe for more insights, and as always, stay informed and stay healthy. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
There is an exciting development in the world of weight loss medication: a pill form of Ozempic, known by its generic name semaglutide. According to The New England Journal of Medicine, those who took the daily semaglutide pill lost nearly fourteen percent of their body weight over sixty-four weeks, compared to just two percent for those who took a placebo. This makes oral semaglutide a potential game changer for those who prefer pills over injections, especially since the pill shows a safety profile similar to the injectable form. Dr. Sean Wharton, who led the recent clinical trial, explained that this oral option could greatly expand the number of people willing to try GLP-1 treatments for obesity.
Following closely behind is orforglipron, a new GLP-1 pill developed by Eli Lilly. Fox News reports that in a recent clinical trial, participants taking the highest dose of orforglipron lost an average of more than twenty-seven pounds after a year and a half. Nearly sixty percent of those participants lost ten percent of their body weight, while just under forty percent lost at least fifteen percent. What is even more hopeful, according to the study published in The New England Journal of Medicine, is that those with pre-diabetes saw a sharp improvement in blood sugar levels, suggesting broad metabolic benefits. While the results are compelling, experts note that injectables like Ozempic still deliver slightly more dramatic results, yet many patients may prefer the convenience and ease of a pill.
On a different front, research from The Cleveland Clinic has revealed that genetics may influence just how well Ozempic or similar drugs work for you. According to their study, a gene known as Neurobeachin appears to help determine how much weight a person might lose with GLP-1 medications. People with a responsive version of the gene were eighty-two percent more likely to have significant weight loss, while those with a non-responsive score were actually less likely to lose weight. Dr. Daniel Rotroff from the Cleveland Clinic suggests that in the near future, doctors could combine genetic testing with lifestyle and personal factors to tailor obesity treatment, making these therapies even more effective and personalized.
Let us not forget the reason why Ozempic was developed in the first place. Originally designed and approved to help manage type two diabetes, Ozempic as well as its higher-dose sibling Wegovy, are now also used for chronic weight management. Both are part of a class called glucagon-like peptide-1 receptor agonists, or GLP-1s. These medications work by stimulating insulin production and helping the body manage appetite and digestion, leading to weight loss as a beneficial side effect. According to information from the Lawsuit Information Center, Ozempic is still mainly prescribed as a once-weekly injection, but with oral versions nearing approval, that could soon change.
New treatments often come with questions about safety. According to the United States Food and Drug Administration, there has been increased concern about unapproved compounded versions of these GLP-1 drugs, which have been linked to hundreds of adverse event reports. This highlights the importance of using only medications that are properly prescribed and approved, as safety must always come first.
Finally, there are ongoing investigations into rare but serious side effects, such as a risk of vision loss, and digestive issues like gastroparesis linked to GLP-1 drugs including Ozempic. For most people, side effects tend to be mild and include nausea and digestive discomfort, but it is crucial to talk to your doctor to understand the potential risks and benefits as this new generation of weight loss options emerges.
That wraps up our update on Ozempic and the evolving world of GLP-1 weight loss therapies. Thanks for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe for more insights, and as always, stay informed and stay healthy. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome back listeners to Ozepic Weight Loss Unlocked. Today we
are uncovering the latest news and updates on ozepic, from
its medical applications to its influence on our daily lives
and overall health. There is an exciting development in the
world of weight loss medication, a pill form of ozepic
known by its generic name semaglutide. According to the New
(00:21):
England Journal of Medicine, those who took the daily semagluetide
pill lost nearly fourteen per cent of their body weight
over sixty four weeks, compared to just two percent for
those who took a placebo. This makes oral semmaglutide a
potential game changer for those who prefer pills over injections,
especially since the pill shows a safety profile similar to
(00:43):
the injectable wall. Doctor Sean Wharton, who led the recent
clinical trial, explained that this oral option could greatly expand
the number of people willing to try GLP one treatments
for obesity. Following closely behind is orpha Lipron, a new
GLP one pill developed by Ellie Lilly. Fox News reports
that in a recent clinical trial, participants taking the highest
(01:04):
dose of orphilipron lost an average of more than twenty
seven pounds. After a year and a half, Nearly sixty
percent of those participants lost ten percent of their body weight,
while just under forty percent lost at least fifteen percent.
What is even more hopeful, according to the study published
in the New England Journal of Medicine, is that those
with pre diabetes saw a sharp improvement in blood sugar levels,
(01:28):
suggesting broad metabolic benefits. While the results are compelling, experts
note that injectables like ozempics still deliver slightly more dramatic results,
Yet many patients may prefer the convenience and ease of
a pill. On a different front, research from the Cleveland
Clinic has revealed that genetics may influence just how well
a zepic or similar drugs work for you. According to
(01:49):
their study, a gene known as neurobeachen appears to help
determine how much weight a person might lose with GLP
one medications. People with the responsive version of the gene
were a eighty two percent more likely to have significant
weight loss, while those with a non responsive score were
actually less likely to lose weight. Doctor Daniel Rotchroff from
the Cleveland Clinic suggests that in the near future, doctors
(02:12):
could combine genetic testing with lifestyle and personal factors to
tailor obesity treatment, making these therapies even more effective and personalized.
Let us not forget the reason why ozepic was developed
in the first place. Originally designed and approved to help
manage type two diabetes a, zepic as well as its
higher dose symbling wegov, are now also used for chronic
(02:34):
weight management. Both are part of a class called glucagin
like peptide ie receptor agonists, or GLP one's s. These
medications work by stimulating insulin production and helping the body
manage appetite and digestion, leading to weight loss as a
beneficial side effect. According to information from the Lawsuit Information Center,
(02:54):
ozepic is still mainly prescribed as a once weekly injection,
but with oral versions nearing approved, that could soon change.
New treatments often come with questions about safety. According to
the United States Food and Drug Administration, there has been
increased concern about unapproved compounded versions of these GLP one drugs,
which have been linked to hundreds of adverse event reports.
(03:17):
This highlights the importance of using only medications that are
properly prescribed and approved, as safety must always come first. Finally,
there are ongoing investigations into rare but serious side effects
such as a risk of vision loss and digestive issues
like gastroparesis linked to GLP one drugs, including ozepic. For
most people, side effects tend to be mild and include
(03:39):
nausea and digestive discomfort, but it is crucial to talk
to your doctor to understand the potential risks and benefits.
Is this new generation of weight loss options emerges That
wraps up our update on ozempic and the evolving world
of GLP one weight loss therapies. Thanks for tuning in
to ozempic weight Loss Unlocked. Do not forget to subscribe
for more in sites, and as always, stay informed and
(04:02):
stay healthy. This has been a quiet please production. For
more check out Quiet please dot ai
Welcome back listeners to Ozepic Weight Loss Unlocked. Today we
are uncovering the latest news and updates on ozepic, from
its medical applications to its influence on our daily lives
and overall health. There is an exciting development in the
world of weight loss medication, a pill form of ozepic
known by its generic name semaglutide. According to the New
(00:21):
England Journal of Medicine, those who took the daily semagluetide
pill lost nearly fourteen per cent of their body weight
over sixty four weeks, compared to just two percent for
those who took a placebo. This makes oral semmaglutide a
potential game changer for those who prefer pills over injections,
especially since the pill shows a safety profile similar to
(00:43):
the injectable wall. Doctor Sean Wharton, who led the recent
clinical trial, explained that this oral option could greatly expand
the number of people willing to try GLP one treatments
for obesity. Following closely behind is orpha Lipron, a new
GLP one pill developed by Ellie Lilly. Fox News reports
that in a recent clinical trial, participants taking the highest
(01:04):
dose of orphilipron lost an average of more than twenty
seven pounds. After a year and a half, Nearly sixty
percent of those participants lost ten percent of their body weight,
while just under forty percent lost at least fifteen percent.
What is even more hopeful, according to the study published
in the New England Journal of Medicine, is that those
with pre diabetes saw a sharp improvement in blood sugar levels,
(01:28):
suggesting broad metabolic benefits. While the results are compelling, experts
note that injectables like ozempics still deliver slightly more dramatic results,
Yet many patients may prefer the convenience and ease of
a pill. On a different front, research from the Cleveland
Clinic has revealed that genetics may influence just how well
a zepic or similar drugs work for you. According to
(01:49):
their study, a gene known as neurobeachen appears to help
determine how much weight a person might lose with GLP
one medications. People with the responsive version of the gene
were a eighty two percent more likely to have significant
weight loss, while those with a non responsive score were
actually less likely to lose weight. Doctor Daniel Rotchroff from
the Cleveland Clinic suggests that in the near future, doctors
(02:12):
could combine genetic testing with lifestyle and personal factors to
tailor obesity treatment, making these therapies even more effective and personalized.
Let us not forget the reason why ozepic was developed
in the first place. Originally designed and approved to help
manage type two diabetes a, zepic as well as its
higher dose symbling wegov, are now also used for chronic
(02:34):
weight management. Both are part of a class called glucagin
like peptide ie receptor agonists, or GLP one's s. These
medications work by stimulating insulin production and helping the body
manage appetite and digestion, leading to weight loss as a
beneficial side effect. According to information from the Lawsuit Information Center,
(02:54):
ozepic is still mainly prescribed as a once weekly injection,
but with oral versions nearing approved, that could soon change.
New treatments often come with questions about safety. According to
the United States Food and Drug Administration, there has been
increased concern about unapproved compounded versions of these GLP one drugs,
which have been linked to hundreds of adverse event reports.
(03:17):
This highlights the importance of using only medications that are
properly prescribed and approved, as safety must always come first. Finally,
there are ongoing investigations into rare but serious side effects
such as a risk of vision loss and digestive issues
like gastroparesis linked to GLP one drugs, including ozepic. For
most people, side effects tend to be mild and include
(03:39):
nausea and digestive discomfort, but it is crucial to talk
to your doctor to understand the potential risks and benefits.
Is this new generation of weight loss options emerges That
wraps up our update on ozempic and the evolving world
of GLP one weight loss therapies. Thanks for tuning in
to ozempic weight Loss Unlocked. Do not forget to subscribe
for more in sites, and as always, stay informed and
(04:02):
stay healthy. This has been a quiet please production. For
more check out Quiet please dot ai
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Are You A Charlotte?
In 1997, actress Kristin Davis’ life was forever changed when she took on the role of Charlotte York in Sex and the City. As we watched Carrie, Samantha, Miranda and Charlotte navigate relationships in NYC, the show helped push once unacceptable conversation topics out of the shadows and altered the narrative around women and sex. We all saw ourselves in them as they searched for fulfillment in life, sex and friendships. Now, Kristin Davis wants to connect with you, the fans, and share untold stories and all the behind the scenes. Together, with Kristin and special guests, what will begin with Sex and the City will evolve into talks about themes that are still so relevant today. "Are you a Charlotte?" is much more than just rewatching this beloved show, it brings the past and the present together as we talk with heart, humor and of course some optimism.